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Abstract
Background: To acquire desirable outcomes of penetrating keratoplasty (PKP), various factors affecting graft
survival, visual function, and subjective symptom should be considered. As ocular surface and meibomian gland
function are associated with these factors, this study aims to investigate changes of ocular surface and meibomian
gland parameters after PKP.
Methods: This retrospective case series study included 24 eyes of 24 patients who underwent penetrating
keratoplasty. Examinations on lipid layer thickness (LLT), meiboscore, tear meniscus area (TMA), tear breakup time
(TBUT), corneal fluorescein staining (CFS), Schirmer I test (SIT), Ocular Surface Disease Index (OSDI), and meibomian
gland functions were performed before and at 1 week, 1 month, 6 months, and 12 months after surgery.
Results: Compared to baseline (2.9 ± 0.6 s), TBUTs were longer at 1 week (4.4 ± 0.5 s, P = 0.027) and 6 months (4.4 ±
0.5, P = 0.048) after surgery. CFS values improved from baseline (6.5 ± 1.1) to 6 months (3.5 ± 0.6, P = 0.023) and 12
months (3.3 ± 0.7, P = 0.001) after surgery. Meibum quality value worsened at 1 week and 12 months after surgery
and meibomian gland expressibility value worsened at 1 week and 6 months after surgery compared to baseline.
OSDI scores improved at 6 and 12 months after surgery. Meiboscore showed no change throughout the follow up
period. The patients with high preoperative meiboscore had worse meibomian gland expressibility at 6 and 12
months and meibum quality at 6 months postoperatively compared to their baseline and to those of patients with
low preoperative meiboscore.
Conclusions: After penetrating keratoplasty, ocular surface parameters including corneal staining, TBUT, and OSDI
significantly improved whereas meibomian gland parameters showed deteriorations, which was marked in patients
with high preoperative meiboscore. Thus, perioperative management of MGD is recommended for patients who
undergo penetrating keratoplasty, especially in patients with advanced MGD.
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Background
Penetrating keratoplasty (PKP) is still a widely per-
formed corneal transplantation procedure for corneal
perforation, full thickness corneal opacity, corneal
dystrophies, bullous keratopathy, and advanced kerato-
conus, when the diseased condition is difficult to treat
with medications such as ointments, bandage contact
lenses, autologous serum, platelet-rich plasma, or lamel-
lar keratoplasty [1–4]. When seeking satisfying outcomes
of PKP, it is important to consider various factors that
affect graft survival, visual function, and subjective
symptoms [1–3]. Common causes for graft failure in-
clude allograft rejection, endothelial decompensation,
and ocular surface diseases (infectious or sterile keratitis,
corneal scarring, etc.) [5]. Additional risk factors for
graft failure are preoperative diagnosis, history of ocular
infection/inflammation, and ocular surface complica-
tions during follow-up (epithelial defect, blepharitis) [6].
Delayed epithelial healing or persistent epithelial defect
after keratoplasty, which aggravates infection, melting,
scarring, and neovascularization, may restrict graft sur-
vival [5, 7]. Even though ocular surface abnormality has
been underrated among the factors related to successful
clinical outcome after PKP, it not only plays an import-
ant role in visual function and subjective symptoms, but
is also a vital factor in graft survival [5, 8]. Ocular sur-
face abnormalities with positive corneal staining are
common after PKP, and tear film instability has been re-
ported to influence visual function postoperatively [8].
Unstable tear film from the neurotrophic state, aqueous
tear deficient state, and persistent ocular surface inflam-
mation after keratoplasty cause dry eye disease (DED),
persistent epithelial defect, neovascularization, and even
allograft rejection [9].
In keratoplasty, tear film and ocular surface are dis-
rupted by various insults. Keratoplasty severs the corneal
nerve and leads to a neurotrophic state, which changes
tear secretion, eyelid blinking, and epithelial growth [9,
10]. Changes in ocular surface anatomy affect normal
tear film distribution [11]; subsequent tear film instabil-
ity and dry eye disease in turn damage visual function
and ocular surface integrity [12]. In this context, main-
taining corneal epithelium, tear film function, and mei-
bomian gland function to achieve homeostasis of the
ocular surface is linked to the postoperative outcome of
keratoplasty [12, 13].
Previous reports have studied changes of tear function,
fluorescein corneal staining, and corneal sensitivity to as-
sess ocular surface abnormalities after keratoplasty [8,
14]. However, despite the ever-growing attention on the
role of meibomian gland function in ocular surface
homeostasis, ocular surface and meibomian gland
dysfunction (MGD) after keratoplasty has not yet been
comprehensively studied [13]. In this study, we
investigated dry eye disease after keratoplasty by evaluat-
ing ocular surface and meibomian gland parameters.
Methods
This retrospective case series study was approved by the
Severance Hospital Institutional Review Board, Seoul,
South Korea (No. 1–2016-0027) and followed the tenets
of the Declaration of Helsinki.
Subjects
Twenty-four eyes from 24 patients who received PKP
between January 2017 and December 2018 were enrolled
in the study. All the patients were followed up for at
least 12 months. Exclusion criteria included a history of
previous keratoplasty, limbal deficiency, Sjogren’s syn-
drome, uncontrolled intraocular pressure, and rejection
episode after the surgery. This study included 24 eyes of
24 patients with a mean age of 54.54 ± 14.39 (range, 31–
82 years). Indications for keratoplasty were bullous
keratopathy (10 eyes), corneal opacity (9 eyes), and ad-
vanced keratoconus (5 eyes).
Surgical technique
PKP was performed by a single experienced surgeon
(T.I.K.) following standardized procedures under general
anesthesia. The recipient cornea trephination diameter
was 7 to 8 mm and the donor corneal diameter was the
same or 0.25 mm larger than that of the recipient’s. The
graft was sutured to the recipient bed with 16
interrupted 10–0 nylon sutures. At the end of the sur-
gery, intraoperative adjustment of sutures was performed
to minimize the risk of corneal astigmatism. Pressure
patch was applied for 3 to 5 days until epithelial defects
are healed.
Postoperatively, topical 0.5% levofloxacin (Cravit,
Santen Pharmaceutical, Osaka, Japan) and topical 1%
prednisolone acetate (PredForte, Allergan, Irvine,
California) were applied four times a day. Topical antibi-
otics were gradually tapered and maintained for 1 year.
Topical steroids were also tapered and maintained for 2
years. Increased intraocular pressure was managed with
glaucoma medication and topical 1% prednisolone was
switched to topical 0.5% loteprednol (Lotemax, Bausch
& Lomb, Rochester, New York) in each patient as
needed. Patients were instructed to use 0.1% hyaluronic
acid artificial tears for dry eye management, as
necessary.
Outcome measures
Detailed examinations of the ocular surface and meibo-
mian gland function were performed by one of the au-
thors (IJ) before surgery and at 1 week, 1 month, 6
months, and 12 months after surgery.
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LLT and noninvasive meibography were obtained from
LipiView II interferometer (TearScience, Morrisville,
NC). Meiboscore was measured from grade 0 (no loss of
gland) to grade 3 (loss of more than two-thirds of the
total gland area) as previously described [15]. TMA of
the lower eyelid was measured using Fourier-domain op-
tical coherence tomography (OCT; RTVue; Optovue,
Inc., Fremont, CA). Vertical 2-mm scan images at the
middle of the lower eyelid were obtained twice for each
eye and TMA was calculated using ReVue software (ver-
sion 4.0; Optovue, Inc., Fremont, CA) [16]. TBUT was
measured three times using a fluorescein strip (Haag-
Streit, Koeniz, Switzerland), and the mean value was col-
lected. Subsequent CFS was graded from 0 to 15 accord-
ing to the National Eye Institute (NEI) scale [17]. SIT
without anesthesia was performed for 5 min at least 10
min after corneal staining. Subjective symptoms were
assessed using the OSDI questionnaire [18]. Meibomian
gland functions were assessed in terms of lid margin ab-
normality, gland expressibility, and meibum quality. Lid
margin abnormalities were graded from 0 to 4 based on
the presence of vascular engorgement, plugged Meibo-
mian gland orifices, displacement of the mucocutaneous
junction, and irregularity of the lid margin [19]. Meibo-
mian gland expressibility was checked by applying firm
digital pressure on the central five glands of the lower
eyelid and was measured as grade 0 if all five glands
expressed and grade 3 if none of the glands expressed
[20]. Meibum quality of eight lower lid glands was
graded from 0 (clear) to 3 (toothpaste-like) and a total
score of up to 24 was acquired [20].
Statistical analysis
All data were analyzed using SPSS for Windows version
23.0 (SPSS Inc., Chicago, IL) and expressed as mean ±
standard deviation. Repeated measure analysis of vari-
ance (RM-ANOVA) was used to analyze the differences
between visits. Paired t-test and Wilcoxon signed-rank
test were used to compare data between two time points
within a group, with adjustment of the level of signifi-
cance according to the Bonferroni correction. Subgroup
analysis and comparison with different characteristics
were performed using independent samples t-test and
Mann-Whitney test. P values less than 0.05 were consid-
ered statistically significant.
Results
Ocular surface and Meibomian gland status after
Keratoplasty
The ocular surface and meibomian gland parameters of
DED after keratoplasty are shown in Table 1. TBUT
values were higher at 1 week and 6months after surgery
than the baseline. Corneal staining scores showed a sig-
nificant reduction from the baseline at 6 and 12months
after surgery. Meibum quality values were elevated at 1
week and 12months after surgery. Meibomian gland
expressibility values were elevated at 1 week and 6
months after surgery. Meiboscore showed no change
throughout the follow-up period. LLT was higher at 1
week postoperatively than the baseline. OSDI scores
were improved at 6 and 12months after surgery com-
pared to the baseline. Other clinical parameters of DED
after surgery were not significantly different from the
Table 1 Clinical Parameters of Dry Eye Disease











40 ± 8 52 ± 9 0.179 42 ± 10 0.819 29 ± 7 0.290 34 ± 6 0.595
TBUT (sec) 2.9 ± 0.6 4.4 ± 0.5 0.027a 3.9 ± 0.5 0.259 4.4 ± 0.5 0.048a 4.3 ± 0.7 0.096
Corneal fluorescein
staining score (0–15)
6.5 ± 1.1 6.7 ± 0.8 0.762 5.1 ± 0.7 0.283 3.5 ± 0.6 0.023a 3.3 ± 0.7 0.001a
Schirmer’s test I value
(mm/5′)
15.4 ± 2.3 17.8 ± 2.2 0.356 13.4 ± 2.4 0.491 16.2 ± 2.3 0.764 16.5 ± 2.2 0.662
Lid margin abnormality
(0–4)
1.9 ± 0.3 2.1 ± 0.2 0.410 1.9 ± 0.2 1.000 1.9 ± 0.2 1.000 2.0 ± 0.3 0.689
Meibum quality (0–24) 8.8 ± 1.4 11.3 ± 1.1 0.033a 10.7 ± 1.2 0.136 11.0 ± 1.3 0.161 12.7 ± 1.1 0.023a
Meibomian gland
expressibility (0–3)
1.3 ± 0.2 1.8 ± 0.2 0.024a 1.6 ± 0.2 0.231 2.0 ± 0.2 0.019a 1.7 ± 0.2 0.083
Meiboscore (0–3) 1.2 ± 0.2 1.3 ± 0.2 – 1.2 ± 0.2 – 1.3 ± 0.2 – 1.3 ± 0.2 –
Lipid layer thickness (nm) 79.0 ± 4.1 95.6 ± 2.5 0.006a 86.9 ± 3.6 0.168 86.7 ± 3.8 0.158 81.1 ± 4.1 0.694
OSDI (0–100) 40.45 ± 4.42 39.73 ± 4.28 0.879 34.13 ± 4.42 0.070 23.14 ± 3.52 0.001a 28.78 ± 3.37 0.002a
TBUT tear break up time, OSDI ocular surface disease index
Results are expressed as mean ± SD
aStatistical significance (P < 0.05)
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baseline. Figure 1 shows the changes in DED parameters
over the course of keratoplasty.
Changes in parameters in groups with different
Meiboscores
Meiboscore of each patient remained unchanged from
the baseline through the whole follow-up period. Pa-
tients were divided into two groups with different mei-
boscores; group 1, levels 0–1 and group 2, levels 2–3
from the baseline examination. Ocular surface parame-
ters and meibomian gland parameters between the two
groups at each time point were compared (Fig. 2). Com-
pared to the baseline, the high meiboscore group showed
significant worsening of meibomian gland expressibility
values at 6 and 12months and meibum quality values at
6 months after surgery. When compared to the low mei-
boscore group, meibomian gland expressibility values in
the high meiboscore group were significantly worse at 6
and 12months after surgery, and meibum quality values
in the high meiboscore group were significantly worse at
6 months after surgery (Table 2). Other parameters
showed no statistical differences between the groups at
each time point.
Effect of Antiglaucoma medication usage on parameters
The number of patients who used antiglaucoma medica-
tions for over 1 month was 11 and those who did not
were 13. These two groups of patients were compared to
analyze the effect of antiglaucoma medications on the
entire ocular surface and meibomian gland parameters.
SIT values were significantly higher in the group that
used antiglaucoma medications in the pre- and postop-
erative period.
Discussion
In this study, we analyzed changes in the ocular surface
and meibomian gland parameters over 12 months of
follow-up for PKP. We found that the corneal fluores-
cein score, TBUT, and OSDI showed a significant im-
provement over time. We also found that meibomian
gland functions, such as meibomian gland expressibility
and meibum quality, significantly deteriorated without
structural changes after PKP, and that the extent of de-
terioration was more prominent in patients with preex-
isting MGD.
PKP has been a widely used corneal transplantation
procedure for various corneal disorders. This procedure
Fig. 1 Clinical parameters of dry eye disease over time. *Statistical significance (P < 0.05) for changes between baseline and follow-up period
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Fig. 2 Clinical parameters of dry eye disease in groups with different meiboscores. Group 1, meiboscore 0–1; Group 2, meiboscore 2–3.
*Statistical significance (P < 0.05) for changes between groups at each time point
Table 2 Meibomian Gland Parameters of Groups with Different Meiboscore





Meibomian gland expressibility (0–3)
Baseline 1.2 ± 0.9 1.7 ± 0.8 0.198
1 week 1.7 ± 0.9 0.046a 2.0 ± 1.0 0.356 0.494
1 month 1.7 ± 1.0 0.095 1.4 ± 0.8 0.356 0.536
6 months 1.7 ± 0.9 0.149 2.7 ± 0.5 0.038a 0.006b
12months 1.4 ± 1.0 0.455 2.6 ± 1.1 0.048a 0.02b
Meibum quality (0–24)
Baseline 7.9 ± 7.2 11.0 ± 6.2 0.325
1 week 11.5 ± 6.0 0.021a 10.9 ± 4.8 0.915 0.796
1 month 11.5 ± 6.0 0.034a 9.7 ± 5.3 0.580 0.611
6 months 7.9 ± 4.1 0.970 18.4 ± 5.0 0.045a 0.001b
12months 11.4 ± 4.7 0.086 15.7 ± 5.8 0.168 0.07
Group 1, meiboscore 0–1; Group 2, meiboscore 2–3
Results are expressed as mean ± SD
aStatistical significance (P < 0.05) between baseline and follow up period in each group
bStatistical significance (P < 0.05) between two groups at each time point
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involves removal of the full-thickness cornea, total sever-
ance of the corneal nerve, intraocular manipulation, and
extensive suturing with resulting ocular surface irregu-
larity. Even after uneventful surgery, ocular discomfort
occurs. A previous study reported that superficial punc-
tate keratopathy and dry eye were common complica-
tions of corneal denervation after PKP [21]. Aggravation
of DED parameters, such as TBUT, corneal fluorescein
stain, Schirmer I test, and corneal esthesiometry, after
keratoplasty, has been previously reported [11, 14, 22].
Distinct from previous reports, the current study investi-
gated meibomian gland parameters in addition to ocular
surface parameters as the two are not separable.
Corneal staining scores showed gradual improvement
from 1 week after surgery to 12 months after surgery.
However, some degree of epithelium damage persisted
even after 12 months. The poor corneal staining scores
at the baseline were caused by primary corneal diseases.
As the preoperative diagnosis of cornea was treated by
keratoplasty and harmful injuries on epithelium induced
by pathologic corneas were cessated, the corneal epithe-
lium regained its integrity and staining scores improved
from baseline which is consistent with a previous report
by Lin et al. [14] Corneal epithelium defect after kerato-
plasty gradually improved but did not completely heal
until the last study visit. The remaining epithelial defect
after keratoplasty are attributable to denervation, discon-
nection from limbal stem cells, frequent use of eye
drops, and aggravation of DED [9, 22]. And deterioration
of meibomian gland function which was observed in our
study also causes epithelial damage via released inflam-
matory mediators and lipids on the ocular surface [23].
Compared to the measurement at the baseline, TBUTs
significantly improved at 1 week and 12months after
surgery. Despite the fact that tear meniscus areas and
Schirmer 1 test values showed no significant changes
compared to those of baseline, the increase in TBUTs
demonstrates an improvement in tear film stability with-
out changes in tear production or volume. OSDI scores
at 6 and 12months after surgery were lower than those
at the baseline. Surgical removal of pathologic cornea
and subsequent corneal denervation after keratoplasty
may have mitigated dry eye sensation at the early post-
operative period. However, restoration of corneal sensa-
tion and deterioration of MGD led to increase in OSDI
scores at 12 months after surgery.
Comprehensive assessment of meibomian gland pa-
rameters using slit-lamp microscopy, meibography, and
interferometry was performed. Meibomian gland expres-
sibility worsened at 1 week and 6months after surgery.
Meibum quality scores showed a trend of worsening
after surgery, and the changes, compared to those at the
baseline, were significant at 1 week and 12months
postoperatively. Lid margin abnormality score and
meiboscore showed no statistically significant change
during the follow-up period. MGD is caused by the stag-
nation of meibum inside the glands, dilation of the
ductal system, and consequent loss of glands. Our hy-
pothesis was that PKP may aggravate all aspects of
MGD. However, only the functional parameters of mei-
bomian glands, such as expressibility and meibum qual-
ity, were altered without any structural changes in the
lid margin and meibomian gland tissues.
Causes of functional changes in meibomian glands are
multifactorial, and the exact underlying mechanism is
unclear. Damage in neural regulation of meibomian
glands may affect meibum secretion. Meibomian glands,
which are surrounded by a dense meshwork of choliner-
gic parasympathetic nerve fibers may have a role in the
neural feedback loop [24, 25]. As the denervation of the
cornea by keratoplasty is known to interfere with the
feedback loop of the lacrimal functional unit [23], a pos-
sible neural dysregulation of meibomian glands after
keratoplasty may contribute to meibum secretion
abnormalities.
Insufficient lid hygiene after keratoplasty may contrib-
ute to the functional deterioration of the meibomian
glands. Lid hygiene is known to reduce lipid by-products
and lipolytic bacteria on the lid margin, which can re-
duce the level of ocular surface MMP-9, improve the
quality of the lipid layer, and alleviate MGD [26–28].
After keratoplasty, patients are usually discouraged from
cleaning their eyelids because of the risk of mechanical
damage to the ocular surface. Lack of lid hygiene, which
causes stagnation of lipids and obstruction of the gland,
may cause functional changes of meibomian gland after
surgery.
The effects of preservatives and antiglaucoma medica-
tions on meibomian glands have been previously re-
ported, and are known to cause functional and
structural changes in meibomian glands [29–31]. Anti-
glaucoma medications cause subclinical inflammation
which results in keratinization of meibomian gland ori-
fice and subsequent stagnation of meibum [29]. Lee
et al. demonstrated worsening of lid margin abnormality,
expressibility of meibum, and meiboscore in patients
using preservative-containing antiglaucoma medications
[30]. However, in our study, the groups with or without
antiglaucoma medications only differed in SIT values.
Because our study was unable to control the variables
related to antiglaucoma medication usage, the results
could not reflect the impact of antiglaucoma medication
on the ocular surface and meibomian glands. Taken to-
gether, the mechanism of MGD after keratoplasty may
involve various insults, including damaged neural regula-
tion of meibomian glands, insufficient lid hygiene,
preservative-containing eyedrops, and antiglaucoma
medications.
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Functional changes of meibomian glands after surgery
have been previously reported in surgeries other than
PKP [32–36]. Unavoidable trauma from cataract surgery
may induce ocular inflammation [37]. Toxicity from eye
drops [38] and lid dysfunction because of intraoperative
use of lid speculum may also contribute to MGD. Our
results are similar to those reported for cataract surger-
ies in that no structural changes occurred while meibo-
mian gland function deteriorated. It can be speculated
that cataract surgery interferes with the ocular surface
and meibomian glands in ways similar to PKP, but their
exact mechanism could not be elucidated in the current
study.
At the baseline, patients were divided into two
groups; high and low meiboscore groups, and the pa-
rameters between the two groups were compared.
Functional parameters, meibomian gland expressibil-
ity, and meibum quality score showed statistically sig-
nificant differences between the two groups. High
meiboscore group had worse expressibility and mei-
bum quality at 6 and 12 months after surgery. Pa-
tients with worse preexisting MGD were more prone
to the functional deterioration of meibomian glands
without any change in meiboscore. MGD starts with
the stagnation of meibomian gland secretion, and
chronic inflammation within the glands leads to sub-
sequent structural changes. Therefore, patients with
structural damage of the glands are more likely to
have long-standing MGD and frail gland function,
which could easily be affected by harmful insults that
lead to functional degradation of the glands.
As a limitation of our study, the sample size was rela-
tively small due to infrequent cases of keratoplasty.
Moreover, a control group was lacking. In addition,
there could be numerous variables affecting the DED pa-
rameters that were not addressed in our study, which
can confound the results. Furthermore, different use of
eye drops, such as steroids, antiglaucoma medications,
and artificial tears, among study participants could not
be controlled and could have affected the results. In-
creased intraocular pressure after keratoplasty is unpre-
dictable and the response to treatment is not uniform.
Thus, use of antiglaucoma medication after surgery is in-
dividualized. The number of antiglaucoma medications
and duration of use are too heterogeneous in patients
and very complicated to control. Further studies with
meticulous study design are needed to assess the effect
of the antiglaucoma medication in post-keratoplasty
patients.
In spite of these limitations, our study showed signifi-
cant clinical improvement in ocular surface conditions,
including better corneal staining and OSDI, and elong-
ation of TBUT. Although greater deterioration of the
functional parameters of MGD after PKP was observed
for the entire observation period, especially among the
patients with an advanced stage of MGD, our findings
suggest that thorough observation of MGD before and
after keratoplasty is necessary to identify and manage
ocular surface and meibomian gland deficits to achieve
more desirable post-keratoplasty results.
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